Kisunla (donanemab-azbt)
$1,738.13
We can help with your prescription. Read the “Prescription Guide”.
You can access this medicine even if it’s not approved in your country. Learn how.
Kisunla (donanemab-azbt) is a prescription medicine for the treatment of Alzheimer’s disease 1.
Kisunla (donanemab-azbt) is currently only approved by the FDA in the USA 2.
Buy Kisunla (donanemab-azbt)
What is Kisunla (donanemab-azbt) for?
Kisunla (donanemab–azbt) is indicated for the treatment of early Alzheimer’s disease. Treatment should be initiated at the mild cognitive impairment or mild dementia stage of the disease [1].
Kisunla (donanemab-azbt) is available as an intravenous infusion [1].
How does Kisunla (donanemab-azbt) work?
Kisunla (donanemab-azbt) works by targeting and helping to remove amyloid beta plaques from the patient’s brain. These plaques are associated with the memory and cognitive problems that characterize Alzheimer’s disease [1].
Where has Kisunla (donanemab-azbt) been approved?
Kisunla (donanemab-azbt) is currently only approved by the FDA in the USA [2].
References:
- HIGHLIGHTS OF PRESCRIBING INFORMATION . Accessdata.fda.gov, Accessed 23 July 2024.
- Alzheimer’s Association Welcomes U.S. FDA Approval of Kisunla (Donanemab). Alzheimer’s Association, Accessed 23 July 2024.
| single-dose vial x 350 mg/20 mL (17.5 mg/mL) | 1,738.13 |
|---|
Be the first to review “Kisunla (donanemab-azbt)”
Related products
Alzheimer's disease
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Reviews
There are no reviews yet.